Canonic – executive interview

In this interview Kenny Green, Edison’s Israel director, discusses Canonic’s recent announcement with the company’s CEO, Dr Arnon Heyman.
Canonic is a subsidiary of Evogene (EVGN, Mcap: US$106m), which is listed on Nasdaq and TASE. Canonic develops medical cannabis products utilising Evogene’s Computational Predictive Biology platform. Canonic’s products are aimed at improving active compound yields, genetic stability and cannabis varieties for specific medical indications. Canonic’s strategy includes the development of cannabis varieties in order to commercialise medical cannabis products independently or through collaborations. Canonic has exclusive access to Evogene’s genomic assets and technology for the development of medical cannabis products. For more information, please visit: https://www.canonicbio.com.

This interview may contain “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates”, or words of similar meaning. For example, Evogene and Canonic are using forward-looking statements in this ETV when they discuss Canonic’s production plans and capabilities for 2022, and its plans to expand its operations and penetrate to additional markets. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, and involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, those risk factors contained in Evogene’s reports filed with applicable securities authorities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.